Clinical Trials Browser

Has results × Has announcements × Dermatologic × Clear all

NCT04099251 2026-04-09

CheckMate76K

Phase 3 Active not recruiting

790 enrolled 18 charts 2 FDA

Melanoma

NCT02360579 2026-03-25

LN-144

Phase 2 Completed

220 enrolled 16 charts 1 FDA

Melanoma

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT02362594 2026-03-05

MK-3475-054

Phase 3 Active not recruiting

1,019 enrolled 16 charts 2 FDA

Melanoma

NCT01909453 2026-02-27

COLUMBUS

Phase 3 Completed

921 enrolled 48 charts 2 FDA

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT03599713 2025-08-05

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Phase 2 Completed

107 enrolled 16 charts 2 FDA

Carcinoma, Merkel Cell

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 3 FDA

Melanoma

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 2 FDA

Melanoma

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Phase 2 Completed

138 enrolled 21 charts 2 FDA

Carcinoma, Basal Cell

NCT03665597 2025-02-10

KEYNOTE-555

Phase 1 Completed

138 enrolled 34 charts 3 FDA

Melanoma

NCT03553836 2024-11-29

KEYNOTE-716

Phase 3 Active not recruiting

976 enrolled 15 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT01728805 2024-04-25

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase 3 Completed

372 enrolled 14 charts 2 FDA

DermatologicLymphoid

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT01682083 2023-08-30

COMBI-AD

Phase 3 Completed

870 enrolled 13 charts 2 FDA

Melanoma, Neoplasms

NCT02267603 2023-07-05

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

Phase 2 Completed

50 enrolled 11 charts 2 FDA

Carcinoma, Merkel Cell